Identification of secreted glycoproteins of human prostate and bladder stromal cells by comparative quantitative proteomics

Prostate

Volumn 69, Issue 1, 2009, Pages 49-61

  Goo, Young Ah ^a,b,c   Liu, Alvin Y ^a,b,c   Ryu, Soyoung ^a   Shaffer, Scott A ^a   Malmström, Lars ^a   Page, Laura ^a   Nguyen, Liem T ^a   Doneanu, Catalin E ^d   Goodlett, David R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^d WATERS CORPORATION   (United States)

Author keywords

Bladder; Prostate; Secreted proteins; Stromal cells

Indexed keywords

CATHEPSIN L; FOLLISTATIN; GLYCOPEPTIDE; GLYCOPROTEIN; PROPROTEIN CONVERTASE 1; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BLADDER; CELL CULTURE; CELL DIFFERENTIATION; CELL INTERACTION; CELL TRANSPORT; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; ION CURRENT; MASS SPECTROMETRY; MESENCHYME CELL; PRIORITY JOURNAL; PROBABILITY; PROSTATE; PROTEIN DETERMINATION; PROTEOMICS; SCORING SYSTEM; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION; VALIDATION STUDY;

EID: 78650421422     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20853     Document Type: Article

References (61)

1. Bissell MJ, Ram TG. Regulation of functional cytodifferentiation and histogenesis in mammary epithelial cells: Role of the extracellular matrix. Environ Health Perspect 1989;80:61-70.
2. Peehl DM. Human prostatic epithelial and stromal cell lines and strains. Urol Oncol 1996;2(4):100-103.
3. Staack A, Hayward SW, Baskin LS, Cunha GR. Molecular, cellular and developmental biology of urothelium as a basis of bladder regeneration. Differentiation 2005;73(4):121-133.
4. Lee C. Role of androgen in prostate growth and regression: Stromal-epithelial interaction. Prostate Suppl 1996;6:52-56.
5. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107(1):1-10.
6. Kedinger M, Lefebvre O, Duluc I, Freund JN, Simon-Assmann P. Cellular and molecular partners involved in gut morphogenesis and differentiation. Philos Trans R Soc Lond B Biol Sci 1998; 353(1370):847-856.
7. Saxen L. What is needed for kidney differentiation and how do we find it? Int J Dev Biol 1999;43(5):377-380.
8. Goo YA, Goodlett DR, Pascal LE, Worthington KD, Vessella RL, True LD, Liu AY. Stromal mesenchyme cell genes of the human
9. prostate and bladder. BMC Urol 2005;5:17.
10. Zhao H, Ramos CF, Brooks JD, Peehl DM. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol 2007;210(1):111-121.
11. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9(13):4792-4801.
12. Dawson LA, Maitland NJ, Turner AJ, Usmani BA. Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer 2004;90(8):1577-1582.
13. Daly-Burns B, Alam TN, Mackay A, Clark J, Shepherd CJ, Rizzo S, Tatoud R, O'Hare MJ, Masters JR, Hudson DL. A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation. Differentiation 2007;75(1):35-48.
14. Lang SH, Smith J, Hyde C, Macintosh C, Stower M, Maitland NJ. Differentiation of prostate epithelial cell cultures by Matrigel/ stromal cell glandular reconstruction. In Vitro Cell Dev Biol Anim 2006;42(8-9):273-280.
15. You X, Yu HM, Cohen-Gould L, Cao B, Symons M, Vande Woude GF, Knudsen BS. Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells. Exp Cell Res 2003;288(2):246-256.
16. Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM, Calvo F. Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer 1997; 71(1):42-48.
17. Yan JX, Sanchez JC, Tonella L, Williams KL, Hochstrasser DF. Studies of quantitative analysis of protein expression in Saccharomyces cerevisiae. Electrophoresis 1999;20(4-5):738-742.
18. Goodlett DR, Keller A, Watts JD, Newitt R, Yi EC, Purvine S, Eng JK, von Haller P, Aebersold R, Kolker E. Differential stable isotope labeling of peptides for quantitation and de novo sequence derivation. Rapid Commun Mass Spectrom 2001; 15(14):1214-1221.
19. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999;17(10):994-999.
20. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY. Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 2008;9:246.
21. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21(6):660-666.
22. Pedrioli PG, Eng JK, Hubley R, Vogelzang M, Deutsch EW, Raught B, Pratt B, Nilsson E, Angeletti RH, Apweiler R, Cheung K, Costello CE, Hermjakob H, Huang S, Julian RK, Kapp E, McComb ME, Oliver SG, Omenn G, Paton NW, Simpson R, Smith R, Taylor CF, Zhu W, Aebersold R. A common open representation of mass spectrometry data and its application to proteomics research. Nat Biotechnol 2004;22(11):1459-1466.
23. Goo YA, Yi EC, Baliga NS, Tao WA, Pan M, Aebersold R, Goodlett DR, Hood L, Ng WV. Proteomic analysis of an extreme halophilic archaeon, Halobacterium sp.NRC-1. Mol Cell Proteo-mics 2003;2(8):506-524.
24. Radulovic D, Jelveh S, Ryu S, Hamilton TG, Foss E, Mao Y, Emili A. Informatics platform for global proteomic profiling and biomarker discovery using liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2004;3(10):984-997.
25. Ryu S, Gallis B, Goo YA, Shaffer A, Radulovic D, Goodlett DR. Comparison of a label-free quantitative proteomic method based on peptide ion current area to the isotope coded affinity tag method. Cancer Inform 2008;4:243-255.
26. Colinge J, Chiappe D, Lagache S, Moniatte M, Bougueleret L. Differential proteomics via probabilistic peptide identification scores. Anal Chem 2005;77(2):596-606.
27. Liu H, Sadygov RG, Yates JR III. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76(14):4193-4201.
28. Wiener MC, Sachs JR, Deyanova EG, Yates NA. Differential mass spectrometry: A label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal Chem 2004;76(20):6085-6096.
29. Liu AY, LaTray L, van Den Engh G. Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate 2000;44(4):303-312.
30. Yi EC, Marelli M, Lee H, Purvine SO, Aebersold R, Aitchison JD, Goodlett DR. Approaching complete peroxisome characterization by gas-phase fractionation. Electrophoresis 2002; 23(18):3205-3216.
31. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25(1):25-29.
32. Goo YA, Pajkovic N, Shaffer S, Goodlett DR, van Breemen R. Systematic investigation of lycopene effects in LNCaP cells by use of novel large-scale proteomic analysis software. Proteomics Clin Appl 2007;1(5):513-523.
33. Chauhan SS, Goldstein LJ, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res 1991;51(5):1478-1481.
34. Staack A, Tolic D, Kristiansen G, Schnorr D, Loening SA, Jung K. Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology2004;63(6):1089-1094.
35. Shuja S, Sheahan K, Murnane MJ. Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int J Cancer 1991;49(3):341-346.
36. Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Hampel G, Schnorr D, Loening SA. Cathepsins B, H, L. and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 1999;35(1):138-144.
37. Adams D, Larman B, Oxburgh L. Developmental expression of mouse follistatin-like 1 (Fstl1): Dynamic regulation during organogenesis of the kidney and lung. Gene Expr Patterns 2007;7(4):491-500.
38. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 2005;65(22):10423-10430.
39. Cunha GR, Cooke PS, Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 2004; 67(5):417-434.
40. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 2005;204(1):36-44. 40. Gorringe KL, Chin SF, Pharoah P, Staines JM, Oliveira C, Edwards PA, Caldas C. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis 2005;26(5):923-930.
41. Leung KC, Brce J, Doyle N, Lee HJ, Leong GM, Sjogren K, Ho KK. Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases. Endocrinology 2007;148(5):2417-2423.
42. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006;127(3):635-648.
43. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 2005;65(4):1325-1334.
44. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87(11):4120-4124.
45. Kang HR, Yim EY, Oh SY, Chang YS, Kim YK, Cho SH, Min KU, Kim YY. Normal C1 inhibitor mRNA expression level in type I hereditary angioedema patients: Newly found C1 inhibitor gene mutations. Allergy 2006;61(2):260-264.
46. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P, Michel MS. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res 2005;25(1A):183-191.
47. Sugimura Y, Cunha GR, Bigsby RM. Androgenic induction of DNA synthesis in prostatic glands induced in the urothelium of testicular feminized (Tfm/Y) mice. Prostate 1986;9(3):217-225.
48. Simanainen U, Allan CM, Lim P, McPherson S, Jimenez M, Zajac JD, Davey RA, Handelsman DJ. Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. Endocrinology 2007;148(5):2264-2272.
49. Cunha GR. Mesenchymal-epithelial interactions: Past, present, and future. Differentiation 2008.
50. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 1999; 140(5):1984-1989.
51. Donjacour AA, Thomson AA, Cunha GR. FGF-10 plays an essential role in the growth of the fetal prostate. Dev Biol 2003; 261(1):39-54.
52. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26(2):263-273.
53. Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, Sorensen CM, Vessella RL, Belldegrun AS, Hood LE. Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate 2004;60(2):98-108.
54. Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, Yi EC, Shannon P, Khrebtukova I, Lange PH, Goodlett DR, Zhou D, Vasicek TJ, Hood L. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: A systems approach to disease. Cancer Res 2005; 65(8):3081-3091.
55. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006;99(2):333-344.
56. Misra UK, Deedwania R, Pizzo SV. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J Biol Chem 2006;281(19): 13694-13707.
57. Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, Lee AS, Cote RJ. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res 2006;12(20 Pt 1):5987-5993.
58. Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A, Flores-Morales A. Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 2006;281(40):29938-29948.
59. Miyagi T, Hori O, Koshida K, Egawa M, Kato H, Kitagawa Y, Ozawa K, Ogawa S, Namiki M. Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells. Int J Urol 2002;9(10):577-585.
60. Scherl A, Shaffer SA, Taylor GK, Kulasekara HD, Miller SI, Goodlett DR. Genome-specific gas-phase fractionation strategy for improved shotgun proteomic profiling of proteotypic peptides. Anal Chem 2008;80(4):1182-1191.
61. Chung LW, Huang WC, Sung SY, Wu D, Odero-Marah V, Nomura T, Shigemura K, Miyagi T, Seo S, Shi C, Molitierno J, Elmore J, Anderson C, Isotani S, Edlund M, Hsieh CL, Wang R, Shehata B, Zhau HE. Stromal-epithelial interaction in prostate ancer progression. Clin Genitourin Cancer 2006;5(2):162-170.